Results 171 to 180 of about 39,808 (354)

5‐HT3 receptor antagonists for preventing postoperative nausea and vomiting after gynecological surgery: A systematic review and network meta‐analysis

open access: yesInternational Journal of Gynecology &Obstetrics, Volume 171, Issue 1, Page 177-189, October 2025.
Abstract Background Gynecological surgery is generally associated with a high risk of postoperative nausea and vomiting (PONV), for which a combination of antiemetic therapies is advised, but adherence to these protocols is often low. Given the current reality, a preferred 5‐HT3 receptor antagonist for preventing PONV as a result of gynecological ...
Hongxia Xu   +7 more
wiley   +1 more source

The antiemetic profile of Y-25130, a new 5-HT3 receptor antagonist

open access: gold, 1990
Takemi Fukuda   +5 more
openalex   +1 more source

Cancer in pregnancy: FIGO Best practice advice and narrative review

open access: yesInternational Journal of Gynecology &Obstetrics, Volume 171, Issue 1, Page 131-151, October 2025.
Abstract Cancer during pregnancy is relatively rare. The incidence is underestimated due to the lack of international registries covering both high‐income and low‐ and middle‐income countries, and is expected to rise with increasing maternal age and increasing global adoption of cell‐free DNA testing for aneuploidy.
Surabhi Nanda   +29 more
wiley   +1 more source

Metabolism and Excretion of Intravenous, Radio-Labeled Amisulpride in Healthy, Adult Volunteers

open access: yesClinical Pharmacology: Advances and Applications, 2019
Gabriel M Fox,1 Ad F Roffel,2 Jan Hartstra,2 Linda A Bussian,3 Sjoerd P van Marle2 1Department of Clinical Development, Acacia Pharma Ltd, Cambridge, UK; 2PRA Health Sciences, Groningen, the Netherlands; 3Comedica Ltd, Cambridge, UKCorrespondence ...
Fox GM   +4 more
doaj  

The Pharmacist's Role in the Use of Incretin‐Based Therapies for Weight Management: An Opinion of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy

open access: yesJACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Volume 8, Issue 10, Page 1078-1093, October 2025.
ABSTRACT The popularity of incretin‐based therapies has increased substantially over the past several years due to their clinically significant efficacy for weight loss and positive impact on weight‐related comorbid conditions, yet, few clinical practice guidelines for the management of overweight and obesity have been updated to incorporate these ...
Sara Lingow   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy